Skin Research and Technology最新文献

Background: This study aimed to establish a novel method for evaluating ultraviolet (UV) protection efficacy on hair, focusing on the relationship between sun protection factor (SPF) and UV-induced hair color changes. We propose a hair SPF (HSPF) that measures the extent of hair color change following UV irradiation.

Materials and methods: In in vitro tests, we used UV standard samples with known SPF values (P2, P5, and P8) to construct a standard curve according to hair color changes before and after UV irradiation. Hair samples were analyzed using the CIELAB color space system, calculating the ΔE value to represent the color difference. To assess the UV protection properties of various hair care formulations (oils, essences, and balms), we compared their HSPF with the standard curve. Meanwhile, in vivo tests followed the ISO 24444 guidelines, involving ten participants to validate the correlation between the in vitro and in vivo methods.

Results: Higher SPF products resulted in smaller ΔE values, indicating less color fading and greater protection. The in vitro HSPF values strongly correlated with the in vivo SPF results, particularly for oils and balms (R² = 0.734). However, formulations with high-moisture content exhibited lower correlation.

Conclusion: The HSPF offers a new perspective on the level of hair protection from UV damage and may be promising for the future development and efficacy testing of UV protection products for hair.

Background: Plantar warts are among the most common skin lesions caused by the human papillomavirus (HPV) and are highly resistant to treatment. Obesity is a well-established factor for skin disease, yet few studies have focused on its association with plantar warts. This study aimed to describe the clinical characteristics of plantar warts and their relationship with body mass index (BMI).

Methods: This retrospective case series included patients with plantar warts treated at the dermatology department of the Third People's Hospital of Hangzhou between May 2023 and March 2025. An electronic medical record system was used to collect participants' demographic and clinical data. Dermoscopy was used to evaluate wart dermatological features, focusing on two key aspects: vascularity and surface patterns. Patients were categorized into two groups based on BMI: BMI ≥ 24.0 kg/m² and BMI < 24.0 kg/m², to compare their dermatological characteristics.

Results: A total of 262 patients with plantar warts were included in the study (average age: 37 ± 12.75 years), with more females (55.73%) than males (44.27%). Most plantar warts were single lesions (66%) and appeared predominantly on the soles (49%) and toes (29%). Dermoscopically, the majority exhibited dotted blood vessels (79%) and a yellow or brown color, both for the background (74%) and surface pattern (68%). Among the 262 patients, 90 were in the BMI ≥ 24.0 kg/m² group (34.25%), and 172 were in the BMI < 24.0 kg/m² group (65.65%). Compared to the BMI< 24 kg/m² group, the BMI≥24 kg/m² group had a significantly higher proportion of males (61.11% vs. 35.47%, p < 0.001), frogspawn (35.56% vs. 19.77%, p = 0.012), and papilliform patterns (7.78% vs. 5.81%). No statistically significant differences were observed in age, number of warts, location, background color, and vascular characteristics between the two groups (p > 0.05).

Conclusions: This case series demonstrate the utility of dermoscopy as a non-invasive and cost-effective tool for identifying and characterizing the features of plantar warts. Our descriptive findings revealed variations in the dermoscopic patterns of plantar warts across different BMI categories. Our findings offer preliminary insights into the clinical presentation of plantar warts, paving the way for future studies with more robust design and statistical analysis.

Background: Melanosis is an acquired hyperpigmentation disorder that can be associated with the use of medications; timely identification and discontinuation of relevant medications is an important aspect of clinical management.

Objective: This study investigates the relationship between melanosis and drug exposure based on data from the FDA Adverse Event Reporting System (FAERS) database. We sought to determine the top drugs reported in association with melanosis in the FAERS.

Methods: A retrospective analysis of FAERS data from January 2004 to June 2024 was conducted to identify reports related to melanosis, using the Comprehensive Medical Dictionary for Regulatory Activities (MedDRA) terminology. A total of 18 182 912 independent adverse event reports were processed, and signal mining analyses were performed to detect associations between drugs and melanosis. Disproportionality analyses were conducted using four algorithms: reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS). The most frequently reported drugs and their associated adverse event reports were analyzed.

Results: Hundred and one reports related to melanosis were screened, involving 73 drug names as primary suspect (PS). By combining and organizing the different names of drugs such as trade names and generic names, 66 drugs were obtained. The top five drugs associated with melanosis were talimogene laherparepvec (ROR: 1891.39), followed by ferrous sulfate (ROR: 997.14), minocycline (ROR: 176.05), vemurafenib (ROR: 97.64), and pembrolizumab (ROR: 19.73).

Conclusion: Patients who experience drug-induced melanosis generally have bad outcomes, underscoring the imperative for heightened clinical surveillance regarding the risk of drug-induced melanosis.